Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

2(40.0%)

Phase 1

2(40.0%)

Phase 3

1(20.0%)

5Total

Phase 2(2)

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07456696Phase 3Recruiting

An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)

Role: lead

NCT05741710Phase 1Completed

A Study to Assess the Use of Methylone in the Treatment of PTSD

Role: lead

NCT06215261Phase 2Completed

An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD

Role: lead

NCT06237426Phase 2Completed

An Evaluation of the Long-term Efficacy and Safety of Methylone for the Treatment of PTSD

Role: lead

NCT06303648Phase 1Completed

A Single, Ascending Dose Evaluation of the Safety, Pharmacokinetics of Methylone in Healthy Subjects

Role: lead

All 5 trials loaded